About Ignyta
Ignyta is a company based in San Diego (United States) founded in 2011 by Gary Firestein was acquired by Roche in December 2017.. Ignyta has raised $96.87 million across 9 funding rounds from investors including Roche, Teva Pharmaceuticals and Great Point Partners. Ignyta operates in a competitive market with competitors including TScan Therapeutics, Imbed Biosciences, GigaGen, Shattuck Labs and Boundless Bio, among others.
- Headquarter San Diego, United States
- Founders Gary Firestein
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ignyta, Inc.
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$13.35 M (USD)67.02as on Mar 31, 2023
-
Net Profit
$1.62 M (USD)27.55as on Mar 31, 2023
-
EBITDA
$2.28 M (USD)25.37as on Mar 31, 2023
-
Total Equity Funding
$96.87 M (USD)
in 9 rounds
-
Latest Funding Round
$160 M (USD), Post-IPO
Oct 20, 2017
-
Investors
Roche
& 4 more
-
Employee Count
Employee Count
-
Acquired by
Roche
(Dec 21, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ignyta
Ignyta has successfully raised a total of $96.87M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $160 million completed in October 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Post-IPO — $160.0M
-
First Round
First Round
(17 Oct 2011)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2017 | Amount | Post-IPO - Ignyta | Valuation |
investors |
|
| May, 2016 | Amount | Post-IPO - Ignyta | Valuation |
investors |
|
| Nov, 2015 | Amount | Post-IPO - Ignyta | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ignyta
Ignyta has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Teva Pharmaceuticals and Great Point Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on company buyouts
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Private equity investments are managed by this USA-based firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ignyta
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ignyta
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ignyta Comparisons
Competitors of Ignyta
Ignyta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Imbed Biosciences, GigaGen, Shattuck Labs and Boundless Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Nanotech-based wound care products are developed and provided.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer are developed by targeting ecDNA.
|
|
| domain | founded_year | HQ Location |
T-cell therapies for cancer treatment are developed by Bolt Biotherapeutics.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ignyta
Frequently Asked Questions about Ignyta
When was Ignyta founded?
Ignyta was founded in 2011.
Where is Ignyta located?
Ignyta is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Ignyta a funded company?
Ignyta is a funded company, having raised a total of $96.87M across 9 funding rounds to date. The company's 1st funding round was a Post-IPO of $30M, raised on Oct 17, 2011.
What is the annual revenue of Ignyta?
Annual revenue of Ignyta is $13.35M as on Mar 31, 2023.
What does Ignyta do?
Ignyta employs an integrated RxDx strategy of combining highly targeted drug discovery and development with companion diagnostics for patient selection. The main drugs in its pipeline include - Entrectinib (An orally available, selective tyrosine kinase inhibitor), Taladegib (A small molecule hedgehogsmoothened antagonist), RXDX-105 (small-molecule multikinase inhibitor), RXDX-107 (an alkyl ester of bendamustine encapsulated in human serum albumin (HSA) to form nanoparticles). Most of these drugs are at an early clinical stage. On the diagnostic side, Ignyta has launched Trailblaze Pharos, a multiplex assay for identifying actionable gene rearrangements in solid tumors that can be treated with entrectinib.
Who are the top competitors of Ignyta?
Ignyta's top competitors include Imbed Biosciences, GigaGen and Shattuck Labs.
Who are Ignyta's investors?
Ignyta has 5 investors. Key investors include Roche, Teva Pharmaceuticals, Great Point Partners, City Hill Ventures, and Colt Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.